nach oben

Erschienen in:

01.07.2009

CD3ζ Expression and T Cell Proliferation are Inhibited by TGF-β1 and IL-10 in Cervical Cancer Patients

verfasst von: Cinthya E. Díaz-Benítez, Karla R. Navarro-Fuentes, Jacqueline A. Flores-Sosa, Janet Juárez-Díaz, Felipe J. Uribe-Salas, Edgar Román-Basaure, Ludwig E. González-Mena, Patricia Alonso de Ruíz, Guillermina López-Estrada, Alfredo Lagunas-Martínez, Victor H. Bermúdez-Morales, Juan M. Alcocer-González, Jesús Martínez-Barnetche, Rogelio Hernández-Pando, Yvonne Rosenstein, José Moreno, Vicente Madrid-Marina

Erschienen in: Journal of Clinical Immunology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Cervical cancer development from a squamous intraepithelial lesion is thought to be favored by an impaired T cell immunity. We evaluated parameters of T cell alterations such as proliferation, cytokine, and CD3ζ expression in peripheral blood and tumor-infiltrating T lymphocytes from women with squamous intraepithelial lesions (SIL) or cervical cancer (CC).

Results and Discussion

T cell proliferation and cytokine messenger RNA (mRNA) expression were similar in women with SIL and healthy donors, whereas low T cell proliferation and lower mRNA expression of IL-2, IL-10 and IFN-γ were observed in women with CC. Moreover, infiltrating cells showed marginal responses. We also found that CD3ζ mRNA expression, whose protein is required for T cell activation, correlated with a decreased proliferation in advanced stages of the disease.

Conclusion

Experiments with T cells from healthy donors in the presence TGF-β1 or IL-10 suggest that these cytokines have a relevant role in T cell responses during CC progression.

Mitchell MF, Hittelman WN, Hong WK, Lotan R, Schottenfeld D. The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. Cancer Epidemiol Biomarkers Prev. 1994;3:619–26.PubMed

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.PubMedCrossRef

Melbye M, Palefsky J, Gonzales J, Ryder LP, Nielsen H, Bergmann O, Pindborg J, Biggar RJ. Immune status as a determinant of human papillomavirus detection and its association with anal epithelial abnormalities. Int J Cancer. 1990;46:203–6. doi:10.1002/ijc.2910460210.PubMedCrossRef

Gentile G, Formelli G, Orsoni G, Rinaldi AM, Busacchi P. Immunosuppression and human genital papillomavirus infection. Eur J Gynaecol Oncol. 1991;12:79–81.PubMed

Nasiell K, Nasiell M, Vaćlavinková V. Behavior of moderate cervical dysplasia during long-term follow-up. Obstet Gynecol. 1983;61:609–14.PubMed

Park TK, Kim SN. Cell-mediated immunity in patients with invasive carcinoma of the cervix. Yonsei Med J. 1989;30:164–72.PubMed

Seder RA, Ahmed R. Similarities and differences in CD4⁺ and CD8⁺ effector and memory T cell generation. Nat Immunol. 2003;4:835–42. doi:10.1038/ni969.PubMedCrossRef

Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006;24:677–88. doi:10.1016/j.immuni.2006.06.002.PubMedCrossRef

Damoiseaux J. Regulatory T cells: back to the future. Neth J Med. 2006;64:4–9.PubMed

10.

Robertson SJ, Hasenkrug KJ. The role of virus-induced regulatory T cells in immunopathology. Springer Semin Immunopathol. 2006;28:51–62. doi:10.1007/s00281-006-0019-2.PubMedCrossRef

11.

Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol. 2001;167:2972–8.PubMed

12.

Alcocer-González JM, Berumen J, Taméz-Guerra R, Bermúdez-Morales V, Peralta-Zaragoza O, Hernández-Pando R, Moreno J, Gariglio P, Madrid-Marina V. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol. 2006;19:481–91. doi:10.1089/vim.2006.19.481.PubMedCrossRef

13.

Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U. Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol. 1999;155:537–47.PubMed

14.

Inge TH, McCoy KM, Susskind BM, Barrett SK, Zhao G, Bear HD. Immunomodulatory effects of transforming growth factor-β on T lymphocytes. Induction of CD8 expression in the CTLL-2 cell line and in normal thymocytes. J Immunol. 1992;148:3847–56.PubMed

15.

Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, Palladino MA. Inhibition of cytokine production by cyclosporin A and transforming growth factorβ. J Exp Med. 1987;166:571–6. doi:10.1084/jem.166.2.571.PubMedCrossRef

16.

Edwards RP, Kuykendall K, Crowley-Nowick P, Partridge EE, Shingleton HM, Mestecky J. T lymphocytes infiltrating advanced grades of cervical neoplasia. CD8-positive cells are recruited to invasion. Cancer. 1995;76:1411–5. doi:10.1002/1097-0142(19951015)76:8<1411::AID-CNCR2820760817>3.0.CO;2-V.PubMedCrossRef

17.

Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH. High number of intraepithelial CD8⁺ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007;67:354–61. doi:10.1158/0008-5472.CAN-06-3388.PubMedCrossRef

18.

Kuss I, Saito T, Johnson JT, Whiteside TL. Clinical significance of decreased ζ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res. 1999;5:329–34.PubMed

19.

Kono K, Ressing ME, Brandt RM, Melief CJ, Potkul RK, Andersson B, Petersson M, Kast WM, Kiessling R. Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res. 1996;2:1825–8.PubMed

20.

de Gruijl TD, Bontkes HJ, Peccatori F, Gallee MP, Helmerhorst TJ, Verheijen RH, Aarbiou J, Mulder WM, Walboomers JM, Meijer CJ, van de Vange N, Scheper RJ. Expression of CD3-ζ on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes. Br J Cancer. 1999;79:1127–32. doi:10.1038/sj.bjc.6690179.PubMedCrossRef

21.

Klausner RD, Samelson LE. T cell antigen receptor activation pathways: the tyrosine kinase connection. Cell. 1991;64:875–8. doi:10.1016/0092-8674(91)90310-U.PubMedCrossRef

22.

Whiteside TL, Miescher S, MacDonald HR, Von Fliedner V. Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients. J Immunol Methods. 1986;90:221–33. doi:10.1016/0022-1759(86)90079-7.PubMedCrossRef

23.

de Gruijl TD, Bontkes HJ, van den Muysenberg AJ, van Oostveen JW, Stukart MJ, Verheijen RH, van der Vange N, Snijders PJ, Meijer CJ, Wallboomers JM, Scheper RJ. Differences in cytokine mRNA profiles between pre-malignant and malignant lesions of the uterine cervix. Eur J Cancer. 1999;35:490–7. doi:10.1016/S0959-8049(98)00371-2.PubMedCrossRef

24.

Bañuelos A, Reyes E, Ocadiz R, Alvarez E, Moreno M, Monroy A, Gariglio P. Neocarzinostatin induces an effective p53-dependent response in human papillomavirus-positive cervical cancer cells. J Pharmacol Exp Ther. 2003;306:671–80. doi:10.1124/jpet.103.051557.PubMedCrossRef

25.

Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP, Hermonat PL. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR⁺ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix. Gynecol Oncol. 2001;81:424–32. doi:10.1006/gyno.2001.6200.PubMedCrossRef

26.

Verduzca-Rodríguez LA, Palet-Guzmán JA, Aguirre-González H, González-Puebla E. Cervico-uterine cancer and age. Ginecol Obstet Mex. 1997;65:119–22.PubMed

27.

Matour D, Melnicoff M, Kaye D, Murasko DM. The role of T cell phenotypes in decreased lymphoproliferation of the elderly. Clin Immunol Immunopathol. 1989;50:82–99. doi:10.1016/0090-1229(89)90224-9.PubMedCrossRef

28.

Curfs JH, Meis JF, Hoogkamp-korstanje JA. A primer on cytokines: sources, receptors, effects and inducers. Clin Microbiol Rev. 1997;10:742–80.PubMed

29.

Fattorossi A, Battaglia A, Ferrandina G, Buzzonetti A, Legge F, Salutari V, Scambia G. Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. Gynecol Oncol. 2004;92:106–15. doi:10.1016/j.ygyno.2003.09.020.PubMedCrossRef

30.

Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, Venzon DJ, Shearer GM, De Palo G, Clerici E. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst. 1997;89:245–50. doi:10.1093/jnci/89.3.245.PubMedCrossRef

31.

Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ, Helmerhorst TJ. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol. 2005;58:1096–100. doi:10.1136/jcp.2004.025072.PubMedCrossRef

32.

Castle PE, Hildesheim A, Bowman FP, Strickler HD, Walker JL, Pustilnik T, Edwards RP, Crowley-Nowick PA. Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. J Clin Immunol. 2002;22:23–7. doi:10.1023/A:1014252402630.PubMedCrossRef

33.

Gey A, Kumari P, Sambandam A, Lecuru F, Cassard L, Badoual C, Fridman C, Nagarajan B, Fridman WH, Tartour E. Identification and characterisation of a group of cervical carcinoma patients with profound downregulation of intratumoral type 1 (IFNgamma) and Type 2 (IL-4) cytokine mRNA expression. Eur J Cancer. 2003;39:595–603. doi:10.1016/S0959-8049(02)00839-0.PubMedCrossRef

34.

Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MGA. CD4⁺ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737–42. doi:10.1038/39614.PubMedCrossRef

35.

Robertson SJ, Hasenkrug KJ. The role of virus-induced regulatory T cells in immunopathology. Springer Semin Immunopathol. 2006;28:51–62. doi:10.1007/s00281-006-0019-2.PubMedCrossRef

36.

von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005;6:338–44. doi:10.1038/ni1180.CrossRef

37.

Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4⁺ CD25⁻ naive T cells to CD4⁺ CD25⁺ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med. 2003;198:1875–86. doi:10.1084/jem.20030152.PubMedCrossRef

38.

Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA. A role for TGF-β in the generation and expansion of CD4⁺CD25⁺ regulatory T cells from human peripheral blood. J Immunol. 2001;166:7282–9.PubMed

39.

Baniyash M. TCR ζ-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol. 2004;4:675–87. doi:10.1038/nri1434.PubMedCrossRef

40.

Tsuzaka K, Nozaki K, Kumazawa C, Shiraishi K, Setoyama Y, Yoshimoto K, Abe T, Takeuchi T. TCRζ mRNA splice variant forms observed in the peripheral blood T cells from systemic lupus erythematosus patients. Springer Semin Immunopathol. 2006;28:185–93. doi:10.1007/s00281-006-0035-2.PubMedCrossRef

41.

Gastman BR, Johnson DE, Whiteside TL, Rabinowich H. Caspase-mediated degradation of T-cell receptor ζ-chain. Cancer Res. 1999;59:1422–7.PubMed

42.

Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 ζ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A. 1996;93:13119–24. doi:10.1073/pnas.93.23.13119.PubMedCrossRef

43.

Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladona ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176:6752–61.PubMed

44.

Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3ζ chain expression by _L-arginine. J Biol Chem. 2002;277:21123–9. doi:10.1074/jbc.M110675200.PubMedCrossRef

45.

Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, Saito S. Expression of indoleamine 2,3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci. 2007;98:874–81. doi:10.1111/j.1349-7006.2007.00470.x.PubMedCrossRef

46.

Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP, Jabbour HN. Cyclooxygenase-2 expression and prostaglandin E₂ synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab. 2001;86:2243–9. doi:10.1210/jc.86.5.2243.PubMedCrossRef

47.

Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. Tumor cyclooxygenase-2/prostaglandin E₂-dependent promotion of FOXP3 expression and CD4⁺ CD25⁺ T regulatory cell activities in lung cancer. Cancer Res. 2005;65:5211–20. doi:10.1158/0008-5472.CAN-05-0141.PubMedCrossRef

48.

Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange. Cancer Res. 2007;67:3976–85. doi:10.1158/0008-5472.CAN-06-4273.PubMedCrossRef

49.

Tjiong MY, van der Vange N, ter Schegget JS, Burger MPM, ten Kate FWJ, Out TA. Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. Cytokine. 2001;14:357–60. doi:10.1006/cyto.2001.0909.PubMedCrossRef

50.

von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Jöhnk C, Henne-Bruns D, Kremer B, Kalthoff H. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res. 2001;7:925s–32s.

51.

Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-β₁ levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg. 1995;222:155–62. doi:10.1097/00000658-199508000-00007.PubMedCrossRef

52.

Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Bröcker EB. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 1995;5:67–8. doi:10.1097/00008390-199502000-00008.PubMedCrossRef

53.

Whiteside TL. Down-regulation of ζ-chain expression in T cell: a biomarker of prognosis in cancer? Cancer Immunol Immunother. 2004;53:865–78.PubMed

54.

Arany I, Grattendick KG, Tyring SK. Interleukin-10 induces transcription of the early promoter of human papillomavirus type 16 (HPV16) through the 5′-segment of the upstream regulatory region (URR). Antiviral Res. 2002;55:331–9. doi:10.1016/S0166-3542(02)00070-0.PubMedCrossRef

55.

Peralta-Zaragoza O, Bermudez-Morales V, Gutierrez-Xicotencatl L, Alcocer-Gonzalez J, Recillas-Targa F, Madrid-Marina V. E6 and E7 oncoproteins from human papillomavirus type 16 induce activation of human transforming growth factor β1 promoter throughout Sp1 recognition sequence. Viral Immunol. 2006;19:468–80. doi:10.1089/vim.2006.19.468.PubMedCrossRef

56.

Kadish AS, Ho GY, Burk RD, Wang Y, Romney SL, Ledwidge R, Angeletti RH. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst. 1997;89:1285–93. doi:10.1093/jnci/89.17.1285.PubMedCrossRef

Titel: CD3ζ Expression and T Cell Proliferation are Inhibited by TGF-β1 and IL-10 in Cervical Cancer Patients
verfasst von: Cinthya E. Díaz-Benítez
Karla R. Navarro-Fuentes
Jacqueline A. Flores-Sosa
Janet Juárez-Díaz
Felipe J. Uribe-Salas
Edgar Román-Basaure
Ludwig E. González-Mena
Patricia Alonso de Ruíz
Guillermina López-Estrada
Alfredo Lagunas-Martínez
Victor H. Bermúdez-Morales
Juan M. Alcocer-González
Jesús Martínez-Barnetche
Rogelio Hernández-Pando
Yvonne Rosenstein
José Moreno
Vicente Madrid-Marina
Publikationsdatum: 01.07.2009
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 4/2009
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-009-9279-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Results and Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

A Randomized Controlled Trial of Oral Administration of Tetanus Toxoid (TT) Versus Tetanus and Reduced Diphtheria (Td) in Pregnant Women

Enhanced Expression of Transcription Factor GATA-4 in Inflammatory Bowel Disease and Its Possible Regulation by TGF-β1

Plasma 1,25 Dihydroxy Vitamin D3 Level and Expression of Vitamin D Receptor and Cathelicidin in Pulmonary Tuberculosis

TLR4 Polymorphisms and Ageing: Implications for the Pathophysiology of Age-Related Diseases

Influence of HLA-DRB1 Alleles on Antibody Responses to PfCP-2.9-Immunized and Naturally Infected Individuals